Goodwin advised 30 Technology on the deal. 30 Technology announced the completed the sale of its antimicrobial nitric oxide platform in certain applications to Convatec Group Plc...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Ducentis BioTherapeutics on the deal. Ducentis BioTherapeutics announced its acquisition by Arcutis Biotherapeutics for up to $400 million. Ducentis BioTherapeutics, a portfolio company of...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Vaccitech on the deal, while Davis Polk advised the representatives of the several underwriters. Vaccitech (Nasdaq: VACC) announced its initial public offering...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Dotmatics, while Willkie Farr & Gallagher LLP advised Insightful Science on the deal. Insightful Science, a leading software provider serving the global...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Vaccitech on the deal. Vaccitech announced the completion of its $168 million Series B, including the conversion of $43 million in convertible loan...
You must be a Standard 1 Year member to access this content.
